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Abstract
Aims: to investigate the association between admission hyperglycemia and myocardial damage in patients
with ST-segment elevation myocardial infarction (STEMI) using Cardiac Magnetic Resonance (CMR).
Methods: We analyzed 113 patients with STEMI treated with successful primary percutaneous coronary
intervention. Admission hyperglycemia was defined as a glucose level ≥ 7.8 mmol/l. Contrast-enhanced
CMR was performed between 3 and 7 days after reperfusion to evaluate left ventricular function and
perfusion data after injection of gadolinium-DTPA. First-pass images (FP), providing assessment of
microvascular obstruction and Late Gadolinium Enhanced images (DE), reflecting the extent of infarction,
were investigated and the extent of transmural tissue damage was determined by visual scores.
Results: Patients with a supramedian FP and DE scores more frequently had left anterior descending
culprit artery (p = 0.02 and <0.001), multivessel disease (p = 0.02 for both) and hyperglycemia (p < 0.001).
Moreover, they were characterized by higher levels of HbA1c (p = 0.01 and 0.04), peak plasma Creatine
Kinase (p < 0.001), left ventricular end-systolic volume (p = 0.005 and <0.001), and lower left ventricular
ejection fraction (p = 0.001 and <0.001).
In a multivariate model, admission hyperglycemia remains independently associated with increased FP and
DE scores.
Conclusion: Our results show the existence of a strong relationship between glucose metabolism
impairment and myocardial damage in patients with STEMI. Further studies are needed to show if
aggressive glucose control improves myocardial perfusion, which could be assessed using CMR.
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Introduction
Admission hyperglycemia is associated with increased
short and long term risk of death in patients with ST-seg-
ment elevation myocardial infarction (STEMI), independ-
ently of the presence of Diabetes Mellitus [1-3]; this
increased mortality might be explained by a higher inci-
dence of congestive heart failure and cardiogenic shock
[2,4]. Moreover, a recent study suggested an association
between admission hyperglycemia and the no-reflow phe-
nomenon as assessed by myocardial contrast echocardi-
ography [5]. In contrast, the association between
hyperglycemia and the extent of myocardial infarct size is
less clear [6-8].
Cardiac Magnetic Resonance (CMR) with a gadolinium-
based contrast agent is considered to accurately assess
myocardial perfusion and function abnormalities after
STEMI. First pass (FP) perfusion provides a valuable
assessment of the extent of microvascular obstruction
(MO) [9], and Late Gadolinium Enhancement (DE)
reflects the extent of myocardial infarction [10,11]. How-
ever, no data are available on the relationship between
admission glycemia and CMR data in the setting of
STEMI.
The objective of the present study was to investigate the
relationship between blood glucose levels taken on
admission and myocardial perfusion parameters assessed




One hundred and thirty one consecutive patients present-
ing with a first acute STEMI and who underwent primary
percutaneous coronary intervention (PCI, angiography
and/or stenting) for arteries exhibiting Thrombolysis In
Myocardial Infarction (TIMI) flow grade < 3, within 24
hours after symptom onset, were included in the study.
Patients with TIMI flow <3 on the culprit lesion after PCI,
or who were hemodynamically unstable or with a con-
traindication for CMR were excluded from the study. The
diagnosis of STEMI was based on prolonged chest pain,
ST-segment elevation ≥ 2 mm in at least two contiguous
electrocardiographic (ECG) leads, and a more than three
fold increase in serum creatine kinase (CK) levels [12,13].
Fourteen patients with a TIMI flow <3 post-PCI and 4
patients with contraindications for CMR were excluded
from the study
Therefore, the study population consisted of 113 patients
(91 men and 22 women, mean age 57 ± 14 years).
All participants gave written consent before entering the
study, in accordance with a protocol approved by the
institutional ethics committee.
Data Collection
Demographic data, age, gender, Body Mass Index (weight/
height2, kg/m2), clinical history of hypertension, diabetes
mellitus, hypercholesterolemia, smoking, previous PCI
and/or Coronary Artery Bypass Graft and peripheral arte-
rial disease were recorded as were on-admission clinical
data (Killip class, ECG and hemodynamic parameters).
Heart failure was defined by Killip class > 1. Location of
MI was determined according to ECG, coronary angio-
graphic and CMR data; no discordance was observed
between the 3 methods. Current treatment before hospi-
talization was also recorded. Blood samples were taken at
admission to measure glucose and C-Reactive Protein lev-
els. HbA1c, HDL-Cholesterol, LDL-Cholesterol and triglyc-
eride levels were assessed from fasting blood sample taken
on the first morning after admission. Peak plasma levels
of Creatine Kinase (CK) were also evaluated and dichot-
omized at ten times the upper normal limit for more clin-
ical relevance. Baseline serum creatinine clearance was
also evaluated by the Cockcroft-Gault formula [14].
CMR protocol
Patients were examined 3 to 7 days after STEMI. Contrast-
enhanced CMR was performed on a 1.5 T whole-body MR
imager (Magnetom Vision, Siemens GmbH, Erlangen,
Germany), using a phased array body coil. Left ventricular
(LV) long-axis scout images were obtained to determine
the orientation of the LV short axis imaging planes.
For LV function evaluation, cine-CMR was performed
using a breath-hold ECG-gated gradient echo sequence
(FLASH 2D), with the following acquisition parameters:
repetition time (TR) 9 ms, echo time (TE) 4.4 ms, pulse
flip angle (α) 15°, 9 lines per segment, field of view (FOV)
of 350 to 400 mm. The acquisition matrix varied from 108
× 256, (12 cardiac cycles), to 144 × 256, (16 cardiac
cycles), depending on the ability of patient to hold his
breath. A series of short-axis slices (thickness of 5 mm
with a gap between slices of 10 mm) was defined from the
base of the heart to the apex [15]. The image of the heart
was taken into account at end-systole and end-diastole
times. A temporal resolution of 50 ms was obtained with
the "view-sharing" technique [16].
For LV perfusion evaluation, a first-pass ECG-gated gradi-
ent echo sequence was performed (T1-weighted turbo-
FLASH sequence) after injection of a bolus of gadolinium-
diethylenetriamine pentaacetic acid (Magnevist, Schering-
AG, Berlin, Germany) into a brachial vein at 0.1 mmol/
Kg; the acquisition parameters were as follows: inversion
time (TI) 400 ms, TR 3.5 ms, TE 1.7 ms, FOV 350 to 400Journal of Cardiovascular Magnetic Resonance 2008, 10:2 http://www.jcmr-online.com/content/10/1/2
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mm, and acquisition matrix 96 × 128, interpolated to 256
× 256. A time delay buffer at the end of the sequence was
adjusted in order to acquire one image every two cardiac
cycles. Three to 5 short-axis slices were obtained from the
base of the heart to the apex, with the same plane as for
the functional study (thickness of 12 mm with a gap
between slices of 3 mm) (Figure 1) [17].
Ten minutes after bolus injection, delayed images were
acquired using a segmented T1-weighted inversion-recov-
ery turboFLASH sequence [18], with the following param-
eters: TR = 2 cardiac cycles; TE = 3.4 ms; α = 25°; FOV =
350 mm; acquisition matrix = 165 × 256, interpolated to
256 × 256, with a variable TI adjusted for each patient
studied in order to optimize the nulling of normal myo-
cardium [19]. This time delay was usually about 250 ms
(Figure 2). The image planes were the same as for func-
tional and first-pass studies (thickness of 8 mm with a gap
between slices of 7 mm).
CMR data analysis
A 17-segment model was used for the data analysis of per-
fusion studies [20]. Left ventricular end-diastolic volume
(EDV) and end-systolic volume (ESV) were calculated
from short-axis views using a method previously
described [15]. Left ventricular ejection fraction (LVEF)
was calculated with the following formula: LVEF = (EDV-
ESV)/EDV. For each patient, perfusion data were analysed and visual
scores were independently attributed by two expert inves-
tigators blinded to clinical data. These scores were given
according to the signal intensity observed on early images
(First-pass images: FP) for 16 segments (the apical seg-
ment was not evaluated on early images, because no long
axis slice was obtained), and late images (delayed
enhanced images: DE, 10 minutes after injection) for each
of the 17 segments (vertical and horizontal long-axis
slices made it possible to evaluate the apical segment).
Early regional hypoenhancement and late regional hyper-
enhancement were scored with a scheme based on the
transmural extent of contrast enhanced tissue within each
segment (0 = no hypo or hyperenhancement; 1 = 1–25%
hypo or hyperenhancement; 2 = 26–50% hypo or hyper-
enhancement; 3 = 51–75 hypo or hyperenhancement; 4 =
76–100% hypo or hyperenhancement). The two scores,
FP, which reflects microvascular obstruction and DE,
which reflects myocardial infarct size, were determined by
calculating the sum of the scores of all of the segments (16
for FP, 17 for DE). Thus, the scores ranged from 0 to 64 for
FP, and from 0 to 68 for DE images [21]. Some areas,
known as no-reflow zones, have major micro-vascular
damage and are characterized by a persistent hypoen-
hanced area even on delayed images [22]. Thus, the
observers were requested to include the no-reflow zones
in the extent of infarction (DE score).
Short axis basal (a), mid-ventricular (b, c) and distal (d) seg- mented Inversion Recovery gradient echo MR images 10  minutes after bolus injection of Gadolinium-DTPA, showing a  large region of myocardial damage (hyperenhancement sur- rounding region of persistent hypoenhancement) in the  antero-septal territory (same patient than Figure 1) Figure 2
Short axis basal (a), mid-ventricular (b, c) and distal (d) seg-
mented Inversion Recovery gradient echo MR images 10 
minutes after bolus injection of Gadolinium-DTPA, showing a 
large region of myocardial damage (hyperenhancement sur-
rounding region of persistent hypoenhancement) in the 
antero-septal territory (same patient than Figure 1).
Short-axis gradient-echo CMR images at basal (a), mid-ven- tricular (b, c) and distal (d) levels, during first pass of a bolus  of gadolinium-DTPA, showing a localized microvascular  obstruction in the antero-septal territory Figure 1
Short-axis gradient-echo CMR images at basal (a), mid-ven-
tricular (b, c) and distal (d) levels, during first pass of a bolus 
of gadolinium-DTPA, showing a localized microvascular 
obstruction in the antero-septal territory.Journal of Cardiovascular Magnetic Resonance 2008, 10:2 http://www.jcmr-online.com/content/10/1/2
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Concordance between expert investigators was satisfac-
tory (interobserver variability <5%). In cases of disagree-
ment, the final decision was taken by consensus.
Statistical analysis
Continuous data were expressed as median (25th percen-
tile – 75th percentile) and dichotomous data as numbers
(percentages).
Patients were categorized according to the median values
of FP and DE scores. Comparison between groups was
made using the Student t test or the Mann-Whitney test for
continuous variables and the Chi square test for discrete
variables. Admission glycemia was dichotomized accord-
ing to presence of hyperglycemia. Hyperglycemia was
defined as glucose levels on admission of ≥ 7.8 mmol/l
(140 mg/dl), in accordance with the guidelines of the
American Diabetes Association [23]. Patients were also
categorized according to the presence of hyperglycemia at
admission, with regard to CMR data.
Multivariate logistic regression analysis was performed to
test for independent predictors of high perfusion scores (>
median value). The following variables, with a p value of
less than 0.1 on univariate analysis were included in the
models: left anterior descending culprit artery, multivessel
disease, TIMI 0 or 1 before PCI, hyperglycemia, HbA1c,
peak CK level, ESV and LVEF. Moreover, age and sex were
also included in the models.
The Spearman rank test was performed to analyse the rela-
tionship between glycemia and perfusion scores.
All the tests were two-sided and a p value <0.05 was con-
sidered as significant.
Statistical analysis was performed with Sigmastat version
2.3 (Statistical Software, SPSS Inc, USA).
Results
Determinants of microvascular obstruction (FP score)
Characteristics of the patients according to the median
value of the FP score are shown in Tables 1 and 2. Patients
with high FP score (>median) more frequently had left
anterior descending culprit artery (p = 0.02), multivessel
disease (p = 0.02) and hyperglycemia (p < 0.001) than
Table 1: Risk factors, biological data and medications according to FP and DE scores: n (%) or median (25th and 75th percentile)
FP score ≤ median 
(n = 57)
FP score > median 
(n = 56)
pD E  s c o r e  ≤ median 
(n = 57)




Age (years) 56 (48–69) 56 (49–68) 0.66 56 (51–68) 57 (48–68) 0.98
Male 43 (75) 48 (86) 0.25 44 (77) 47 (84) 0.51
BMI (kg/m2) 25 (24–28) 26 (24–28) 0.35 25 (24–29) 25 (24–28) 0.54
Hypertension 25 (44) 16 (29) 0.14 22 (39) 19 (34) 0.75
Diabetes 5 (9) 7 (12) 0.74 6 (11) 6 (11) 0.79
Hypercholesterolemia 19 (33) 23 (41) 0.51 23 (40) 19 (34) 0.61
Smoking 23 (40) 29 (52) 0.30 22 (39) 30 (54) 0.42
Previous PCI or CABG 2 (4) 2 (4) 1.00 3 (5) 1 (2) 0.62
Peripheral arterial disease 2 (4) 2 (4) 1.00 2 (4) 2 (4) 1.00
Biological data
Hyperglycemia (≥ 7.8 mmol/l) 17 (30) 35 (63) <0.001 16 (28) 36 (64) <0.001
Glycemia (mmol/l) 7.0 (6.1–8.4) 8.4 (6.9–9.7) 0.001 6.9 (5.9–8.2) 8.4 (7.0–9.6) <0.001
HbA1c (%) 5.4 (5.2–5.7) 5.7 (5.4–6.3) 0.01 5.5 (5.2–5.7) 5.7 (5.4–6.3) 0.04
Peak CK >10 fold UNL 21 (37) 45 (80) <0.001 17 (30) 49 (88) <0.001
CRP (mg/l) 2.2 (1.7–10.0) 4.6 (2.0–11.0) 0.48 2.5 (2.0–11.0) 4.7 (2.0–9.0) 0.81
Creatinine clearance (ml/mn) 87 (73–116) 92 (75–111) 0.48 92 (74–117) 88 (72–111) 0.77
HDL-Cholesterol (mmol/l) 1.04 (0.91–1.33) 1.17 (0.96–1.41) 0.15 1.08 (0.91–1.33) 1.17 (0.94–1.34) 0.50
LDL-Cholesterol (mmol/l) 2.99 (2.49–3.73) 3.01 (2.49–3.90) 0.74 2.93 (2.47–3.79) 3.19 (2.56–3.84) 0.54
Triglyceride (mmol/l) 1.42 (0.92–2.5) 1.29 (0.97–1.73) 0.22 1.45 (1.01–2.4) 1.26 (0.90–1.79) 0.08
Current treatment
Statin 6 (11) 8 (14) 0.75 6 (11) 8 (14) 0.75
Insulin 1 (2) 0 (0) 0.99 1 (2) 0 (0) 0.99
ACE inhibitor 6 (11) 3 (5) 0.51 3 (5) 6 (11) 0.47
Beta Blocker 10 (18) 6 (11) 0.44 9 (16) 7 (13) 0.82
Oral antidiabetic 2 (4) 4 (7) 0.66 2 (4) 4 (7) 0.66
Acute medications
Gp IIb/IIIa receptor blocker 30 (53) 23 (41) 0.30 24 (42) 29 (52) 0.40
Antiplatelet 48 (84) 52 (93) 0.25 48 (84) 52 (93) 0.25
ACE = Angiotensin-Converting Enzyme; BMI = Body Mass Index; CABG = Coronary Artery Bypass Graft; CK = Creatine Kinase; CRP = C-Reactive 
Protein; PCI = Percutaneous Coronary Intervention; SBP = Systolic Blood Pressure; UNL = Upper Normal Limit.Journal of Cardiovascular Magnetic Resonance 2008, 10:2 http://www.jcmr-online.com/content/10/1/2
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patients with low FP score. Moreover, the level of HbA1c
(p = 0.01), peak CK (p < 0.001), ESV (p = 0.005) and DE
score (p < 0.001) were higher in patients with a high FP
score. In contrast, LVEF was lower in the group with a high
FP score (p < 0.001).
Multivariate analysis showed that peak CK (odds ratio
[OR] 4.2; 95% confidence interval [CI] 1.6–11.1; p =
0.004) and hyperglycemia (OR 3.8; 95% CI 1.4–9.9; p =
0.007) were independent predictors of high (supra-
median) FP scores. However, when DE score was included
in the multivariate model, only DE remained an inde-
pendent predictor of high FP score (Table 3).
Determinants of myocardial infarct size (DE score)
Patients with high DE scores (> median) had increased
risk of left anterior descending culprit artery (p < 0.001),
TIMI 0 or 1 before PCI in culprit artery (p = 0.003) and
hyperglycemia (p = <0.001) (Tables 1 and 2). HbA1c (p =
0.04), peak CK (p < 0.001), EDV (p = 0.01), ESV (p <
0.001) and FP score (p < 0.001) were also increased in this
group. In contrast, LVEF (p < 0.001) was significantly
decreased in patients with higher DE scores. Multivariate
analysis showed that hyperglycemia (OR 10.4; 95% CI
2.8–40.3; p < 0.001), left anterior descending culprit
artery (OR 6.6; 95% CI 1.7–25.4; p = 0.006) and peak CK
(OR 19.2; 95% CI 4.8–76.7; p < 0.001) were independent
predictors of high DE scores. When FP score was included
Table 2: Clinical data, coronary angiographic data, and CMR data according to FP and DE scores: n (%) or median (25th and 75th 
percentile)
FP score ≤ median 
(n = 57)
FP score > median 
(n = 56)
pD E  s c o r e  ≤ median 
(n = 57)




Heart failure 8 (14) 3 (5) 0.22 6 (11) 5 (9) 0.98
Heart rate (beats/min) 75 (65–84) 75 (61–80) 0.49 76 (64–84) 75 (62–80) 0.39
Blood pressure
SBP (mm/Hg) 140 (120–155) 140 (120–160) 0.84 140 (120–153) 140 (120–160) 0.87
DBP (mm/Hg) 84 (70–95) 80 (70–99) 0.85 84 (70–94) 80 (70–100) 0.90
Heart rate-SBP product 10477 (8100–12775) 9660 (7874–12600) 0.29 10077 (7800–12915) 9975 (8000–12464) 0.29
Coronary angiographic data
Culprit artery
Left anterior descending 20 (35) 33 (59) 0.02 16 (28) 37 (66) <0.001
Left circumflex 7 (12) 5 (9) 0.79 9 (16) 3 (5) 0.41
Right coronary 30 (53) 18 (32) 0.04 32 (56) 16 (29) 0.006
Location of lesion (% proximal/mid/distal) 30/58/12 36/55/9 0.79 26/64/10 40/49/11 0.28
TIMI 0/1 pre-PCI in culprit artery 35 (61) 42 (75) 0.18 31 (54) 46 (82) 0.003
Multivessel disease 19 (33) 30 (54) 0.02 19 (33) 30 (54) 0.02
Stenting 56 (98) 55 (98) 0.48 55 (96) 56 (100) 0.48
Stent length > 15 mm 17 (30) 19 (34) 0.79 18 (32) 18 (32) 0.89
Stent width > 3 mm 15 (26) 13 (23) 0.87 15 (26) 13 (23) 0.87
IABP use 1 (2) 2 (4) 0.99 0 (0) 3 (5) 0.24
Time to reperfusion (min) 205 (145–399) 187 (130–265) 0.19 189 (134–339) 190 (130–265) 0.43
CMR data
FP score 2 (0–4) 13 (9–19) 2 (0–6) 11 (7–15) <0.001
DE score 10 (4–15) 20 (16–28) <0.001 9 (4–12) 23 (18–29)
LVEF (%) 54 (48–59) 46 (38–56) 0.001 55 (48–60) 44 (37–55) <0.001
EDV (ml) 132 (117–165) 154 (130–177) 0.06 132 (117–160) 155 (130–178) 0.01
ESV (ml) 66 (50–77) 77 (59–100) 0.005 57 (48–74) 83 (63–103) <0.001
DBP = Diastolic Blood Pressure; DE = Delayed-Enhancement; EDV = End Diastolic Volume; ESV = End Systolic Volume; FP = First Pass; IABP = 
Intra-Aortic Balloon Pumping; LVEF = Left Ventricular Ejection Fraction; PCI = Percutaneous Coronary Intervention; SBP = Systolic Blood Pressure.
Table 3: CMR data according to admission hyperglycemia. All values are expressed as median (25th – 75th percentile)
Without hyperglycemia (n = 61) With hyperglycemia (n = 52) p
FP score 4 (0–8) 10 (5–16) <0.001
DE score 11 (6–19) 18 (14–26) <0.001
LVEF (%) 53 (43–59) 50 (43–56) 0.38
EDV (ml) 148 (125–170) 142 (117–173) 0.23
ESV (ml) 69 (55–84) 68 (51–95) 0.85
DE = Delayed-Enhancement; EDV = End Diastolic Volume; ESV = End Systolic Volume; FP = First Pass; LVEF = Left Ventricular Ejection Fraction.Journal of Cardiovascular Magnetic Resonance 2008, 10:2 http://www.jcmr-online.com/content/10/1/2
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in the multivariate model, hyperglycemia, left anterior
descending culprit artery, peak CK, and FP score remained
independent predictors of high DE score (Table 3).
Hyperglycemia and perfusion scores
Spearman rank correlation analysis showed a positive
relationship between admission glycemia and perfusion
scores (r = +0.34 and p < 0.001 for the FP score; r = +0.32
and p < 0.001 for the DE score). Categorization of patients
according to the presence of hyperglycemia showed that
FP (4 [0–8] vs 10 [5-16]; p < 0.001) and DE scores (11 [6-
19] vs 18 [14-26]; p < 0.001) were higher in patients with
hyperglycemia. In contrast, there was no difference
between the 2 groups for LVEF (53 [43–59] vs 50 [43–56]
%; p = 0.38), EDV (148 [125–170] vs 142 [117–173] ml;
p = 0.23) and ESV (69 [55–84] vs 68 [51–95] ml; p =
0.85).
Discussion
The major findings of the present study are that admission
hyperglycemia, in the setting of an acute STEMI, is associ-
ated with the extent of MO as assessed by CMR. Hypergly-
cemia was also an independent predictor of myocardial
infarct size.
Hyperglycemia and microvascular obstruction
First-pass hypoenhancement is recognized as closely
defining the extent of MO [24], and is strongly associated
with worse outcome after STEMI [25-27]. MO is a major
factor involved in the development of the angiographic
"no-reflow" phenomenon, and limits the benefits of
reperfusion [28]. MO may result from leukocyte entrap-
ment in capillaries [29], and from distal microemboliza-
tion of platelets which aggregate and adhere to capillary
walls following plaque rupture [30].
In the present study, admission hyperglycemia was a pre-
dictive factor for the extent of MO, as assessed by the FP
score. To the best of our knowledge, this is the first study
to analyse the relationship between acute hyperglycemia
and MO assessed by CMR, after successful reperfusion.
Nevertheless, these findings are in agreement with those
of Iwakura et al, who investigated the impact of admission
hyperglycemia and the no-reflow phenomenon, assessed
by intracoronary myocardial contrast echocardiography
immediately after successful reperfusion [5]. They found
that hyperglycemia was the strongest predictive factor for
no-reflow.
The potential mechanisms involved in this relationship
have yet to be elucidated. Even so, acute hyperglycemia is
associated with increased platelet activation and fibrinol-
ysis [31], as well as plugging of capillaries by leukocytes
[32]. Acute hyperglycemia may also attenuate endothe-
lium dependent vasodilatation, and reduce collateral
blood flow to the area at risk [33]. Moreover, hyperglyc-
emia may reduce the impact of ischemic preconditioning,
through the attenuation of mitochondrial adenosine tri-
phosphate-regulated K channel activation [34]. All of
these mechanisms could strongly interact to favor the
development of MO. However, in our study MO was
mainly related to myocardial infarct size; which could
partly explain the relation observed between hyperglyc-
emia and MO.
Hyperglycemia and myocardial infarct size
CMR, with Late Gadolinium Enhancement is widely used
to define infarct size. Extra-cellular contrast-agents accu-
mulate in the myocardium due to increased capillary per-
meability oedema, increased extra-cellular space and
slower kinetics in infarcted regions [24,35]. One major
finding of the present work was the close relationship
between admission glycemia and the extent of myocardial
infarction assessed by the DE score, independently of pre-
existing glucose metabolism (HbA1c) or markers of myo-
cardial infarct size (peak CK value). The impact of stress
hyperglycemia on the extent of myocardial necrosis is not
fully understood. Acute hyperglycemia may increase the
inflammatory response during STEMI, and could thus
influence microvascular permeability and oedema [36].
Moreover, in a recent study, Timmer et al found that, in
patients with STEMI, admission hyperglycemia was an
important predictor of reduced epicardial flow in the inf-
arct-related vessel before reperfusion therapy [37]. They
also suggest that acute rather than chronic hyperglycemia
is more important in predicting TIMI flow in patients after
PCI.
Finally, admission hyperglycemia may not only be the
cause of more severe myocardial damage, but also its con-
sequence. Large myocardial infarcts are more likely to
cause excessive secretion of catecholamine, which affect
fatty acids and glucose homeostasis [38]. However, stress
hyperglycemia is an imperfect marker of cardiac damage,
as many other markers in addition to stress hormones
contribute to glucose metabolism [2].
Study limitations
Follow-up data were not available in this study, which
attenuates the impact of the study conclusion.
For evaluation of perfusion and Late Gadolinium
enhancement, we did not use a real quantitative method
but a semi-quantitative visual method to grade the extent
of transmural myocardial damage [11,22]. However, the
17 segment model, which has gained wide acceptance in
scintigraphic myocardial perfusion imaging, is both easy
to obtain and reproducible. Moreoever in a previous study
we showed an excellent correlation and concordanceJournal of Cardiovascular Magnetic Resonance 2008, 10:2 http://www.jcmr-online.com/content/10/1/2
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between visual grading and planimetric evaluation of
myocardial enhancement [21].
The correlation between glycemia and perfusion scores,
although significant, was weak. This relation was consoli-
dated by the analysis of determinants of supramedian per-
fusion scores (Table 1). However, the relationship
between admission glycemia and FP or DE parameter
needs to be demonstrated in larger study population.
Conclusion
Abnormal glucose metabolism is strongly associated with
MO and the extent of myocardial infarct in successfully
reperfused STEMI, as assessed by CMR. These results
emphasize the interest of aggressive glucose control at the
acute phase of STEMI. Moreover, CMR could play a major




CMR: Cardiac Magnetic Resonance Imaging;
DE: Delayed Contrast-Enhanced;
EDV: Left Ventricular End Diastolic Volume;
ESV: Left Ventricular End Systolic Volume;
FP: First Pass;
LVEF: Left Ventricular Ejection Fraction;
MO: Microvascular Obstruction;
PCI: Percutaneous Coronary Intervention;
STEMI: ST-Segment Elevation Myocardial Infarction;
TIMI: Thrombolysis in Myocardial Infarction.
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